Login to Your Account



Philogen IPO a No-Go After Bayer Nixes Antibody Deal

By Nuala Moran


Friday, February 18, 2011
LONDON – Philogen SpA pulled its initial public offering on the Milan Stock Exchange after partner Bayer Schering Pharma AG peremptorily terminated a licensing and collaboration deal between the two for the development of vascular-targeting antibodies in the treatment of cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription